AMOEBA (EPA:ALMIB) - 1 PRESS RELEASE Lyon, 8th June 2018 ORDINARY AND EXTRAORDINARY ANNUAL GENERAL MEETING TO BE HELD ON 21st JUNE 2018
Transparency directive : regulatory news
08/06/2018 17:45
Click here to download pdf version
PRESS RELEASE
Lyon, 8th June 2018
ORDINARY AND EXTRAORDINARY ANNUAL GENERAL MEETING TO BE HELD ON 21st JUNE 2018
MODALITIES THROUGH WHICH THE PREPARATORY DOCUMENTS WILL BE MADE AVAILABLE
The company's shareholders are invited to attend the ordinary and extraordinary
annual general meetings which will be held at:
10 am, Thursday 21st June in the Hotel Kyriad Prestige Lyon Saint-Priest
Eurexpo, Parc Technoland ZI Champ Dolin, 9 Rue Aimé Cotton - 69800
Saint-Priest
The notice of the meeting, including the agenda and the planned resolutions,
was published in the BALO (Bulletin of obligatory legal announcements) of 14th
May 2018; the notice convening the meeting was published in the BALO of 4th
June 2018.
The documents stipulated by article R.225-83 of the French commercial code are
available to shareholders from the moment that the assembly is convened, in
line with the applicable regulatory requirements:
* Any named shareholder can, until the fifth day (inclusive) before the
assembly, ask the company to send them these documents. For holders of bearer
shares, this right can only be exercised upon presentation of a statement of
participation in the accounts of bearer shares held by the authorised
intermediary;
* Any shareholder can consult these documents at the company's headquarters
during the 15 days preceding the date of the assembly.
About AMOEBA:
Amoéba's ambition is to become the world leader in the treatment of bacterial
risk in the fields of water, healthcare and plant protection. Our biological
solution is an alternative to chemical products widely used today. Amoéba is
currently focusing on the market of industrial cooling towers estimated at
EUR1.7Bn (1) on a global chemical biocide market for water treatment, evaluated
at EUR21Bn (2) and on the biocontrol market for plant protection estimated
globally at EUR1.6Bn (4). In the future, the Company is looking at developing
new applications such as chronic wound care, estimated at EUR 751 million (3)
in the USA. Sales of associated products with healthcare, biocides and crop
protection are subject to the Company being granted local regulatory market
authorizations.
Created in 2010, based in Chassieu (Lyon, France) with a subsidiary in Canada
and in the United States, Amoéba is quoted on the compartment C of Euronext
Paris. The Company is a member of the BPIfrance Excellence network and is
eligible for the PEA-PME SME equity savings plan setup. More information on
www.amoeba-biocide.com.
(1): Amoéba data combined from sources: DRIRE 2013, Eurostat, ARHIA 2013
(2): Sources combined by Amoéba from water treaters, Freedonia, Eurostat et
MarketsandMarkets
(3): BCC Research, "Markets for Advanced Wound Management Technologies,"
Wellesley, MA, 2017
(4): Biopesticides Worldwide Market 2013, CPL, Wallingford, UK
Contacts:
Amoéba
Nathalie COMBROUSSE
Marketing Communication Manager
Tel. : +33 (0)4 81 09 18 15
nathalie.combrousse@amoeba-biocide.com
Actifin
Ghislaine GASPARETTO
Financial communication
+33(0)1 5688 1111
ggasparetto@actifin.fr